Viscosupplementation Market By Product (Single Injection, 3 Injections, 5 Injections); By Source of Origin (Avian Origin, Non-avian Origin); By End Use (Hospitals, Orthopedic Clinics, Ambulatory Surgical Centers (ASCs), Other End Users); By Geography – Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032
Viscosupplementation Market size was valued at USD 5.29 billion in 2024 and is anticipated to reach USD 8.37 billion by 2032, expanding at a CAGR of 5.91% during the forecast period.
REPORT ATTRIBUTE
DETAILS
Historical Period
2020-2023
Base Year
2024
Forecast Period
2025-2032
Viscosupplementation Market Size 2024
USD 5.29 Billion
Viscosupplementation Market, CAGR
5.91%
Viscosupplementation Market Size 2032
USD 8.37 Billion
The Viscosupplementation Market grows through rising osteoarthritis prevalence, an aging population, and increasing demand for non-surgical pain management solutions. Patients and physicians prefer minimally invasive injections that restore joint function and delay surgical interventions.
North America leads the viscosupplementation market with strong adoption in the United States, supported by advanced healthcare infrastructure, favorable reimbursement policies, and high awareness of osteoarthritis management. Europe follows with steady growth, driven by the presence of specialized orthopedic clinics and a rising elderly population that demands non-surgical pain relief options. Asia-Pacific emerges as the fastest-growing region, fueled by increasing cases of osteoarthritis in aging populations across China, Japan, and India, along with growing investments in healthcare access. Latin America and Middle East & Africa show gradual progress with rising adoption in private healthcare facilities. Key players shaping the Viscosupplementation Market include Anika Therapeutics, Bioventus, Fidia Pharma, and Seikagaku Corporation, all focusing on advanced hyaluronic acid formulations and expanding clinical applications. Anika Therapeutics is recognized for its FDA-approved single-injection therapies, while Bioventus expands its portfolio with biologics. Fidia Pharma emphasizes innovative HA-based treatments, and Seikagaku Corporation invests heavily in R&D for next-generation viscosupplements.
Market Insights
Viscosupplementation Market size was valued at USD 5.29 billion in 2024 and is projected to reach USD 8.37 billion by 2032, expanding at a CAGR of 5.91%.
Rising prevalence of osteoarthritis and aging populations drive strong demand for non-surgical treatment options that restore joint mobility.
Market trends highlight growing adoption of single-injection regimens, expansion into hip and shoulder applications, and advances in cross-linked hyaluronic acid formulations.
Competitive landscape features key players such as Anika Therapeutics, Bioventus, Fidia Pharma, and Seikagaku Corporation, each focusing on product innovation and global market reach.
Limited reimbursement policies in certain regions, high treatment costs, and variable clinical outcomes act as key restraints for manufacturers and healthcare providers.
North America leads with advanced healthcare infrastructure and strong patient awareness, Europe grows through established orthopedic practices, Asia-Pacific expands rapidly with rising osteoarthritis prevalence, while Latin America and Middle East & Africa show steady progress with private healthcare adoption.
Expanding opportunities in regenerative medicine, integration with platelet-rich plasma therapies, and rising investments in emerging economies position viscosupplementation as a critical component of future orthopedic care.
Access crucial information at unmatched prices!
Request your sample report today & start making informed decisions powered by Credence Research Inc.!
The growing burden of osteoarthritis worldwide drives strong demand for viscosupplementation treatments. Increasing elderly populations and lifestyle changes contribute to joint degeneration and chronic pain. Viscosupplementation Market benefits from its role in managing knee osteoarthritis and delaying surgical interventions. It provides relief by restoring the viscoelastic properties of synovial fluid. Rising incidence among younger patients due to obesity and sports injuries further supports demand. This trend strengthens the adoption of non-surgical solutions in orthopedics.
For instance, Seikagaku Corporation’s ONO‑5704/SI‑613 showed a 6.1 mm greater reduction in WOMAC pain score versus placebo at 12 weeks in a Phase III trial involving 220 patients.
Preference for Minimally Invasive Therapies
Patients increasingly prefer minimally invasive options over surgical procedures for joint pain management. Viscosupplementation offers targeted relief without extended recovery time or hospital stays. It helps reduce dependence on oral pain medications and systemic therapies. Physicians recommend injections to improve mobility and delay the need for joint replacement surgery. The growing acceptance of minimally invasive approaches across healthcare systems supports this trend. Viscosupplementation Market continues to expand as awareness of such treatments rises.
For instance, Anika Therapeutics’ Monovisc is a single-injection, high–molecular weight hyaluronic acid therapy that delivers 88 mg of HA in a 4 mL syringe, equivalent to three injections of an earlier regimen, providing broader relief with one injection.
Growing Adoption in Sports Medicine
The rise in sports injuries among professional and recreational athletes boosts the use of viscosupplementation. Injections help athletes manage cartilage damage and joint pain effectively. It restores functionality and supports faster return to training and competition. Sports medicine specialists adopt viscosupplementation as part of treatment regimens for knee and hip injuries. Increasing focus on joint preservation strengthens demand in younger, active populations. The market gains momentum as sports healthcare centers adopt these therapies widely.
Technological Advancements and Product Innovation
Continuous improvements in hyaluronic acid formulations enhance efficacy and safety of viscosupplementation. Companies develop products with higher molecular weight and longer-lasting effects. It allows fewer injections per treatment cycle, improving patient compliance. Advances in cross-linking technologies extend product durability and clinical outcomes. Research on novel delivery systems, including single-injection regimens, strengthens adoption across diverse patient groups. The Viscosupplementation Market expands as innovation ensures more effective and patient-friendly treatment options.
Market Trends
Shift Toward Single-Injection Formulations
Manufacturers are focusing on developing single-injection viscosupplementation therapies to improve patient compliance. Traditional multi-injection regimens often face challenges with patient adherence and higher treatment costs. The trend toward single-dose solutions reduces clinic visits and enhances convenience. Viscosupplementation Market benefits from this shift by offering effective pain relief with fewer procedures. It strengthens adoption among patients seeking faster and more efficient treatment cycles. Clinical studies continue to validate the long-term effectiveness of single-injection therapies.
For instance, Monovisc is a single 4 mL injection containing 88 mg of high-molecular-weight hyaluronan, which delivers a dose comparable to some three-injection regimens. Clinical studies have shown that a single injection can provide pain relief for knee osteoarthritis that lasts up to 26 weeks, or about six months.
Integration into Combination Therapies
Viscosupplementation is increasingly being used in combination with other non-surgical treatments. Physicians pair it with platelet-rich plasma (PRP) or stem cell therapy to improve outcomes. It offers enhanced cartilage protection and better joint mobility when combined with biologic approaches. The trend reflects growing interest in multimodal treatments for osteoarthritis. Viscosupplementation Market expands its clinical utility through integration into regenerative medicine practices. Research collaborations support innovation in combined therapy protocols.
Expansion Beyond Knee Osteoarthritis
While knee osteoarthritis remains the largest application, adoption is spreading to other joints. Physicians now use viscosupplementation for hip, shoulder, and ankle osteoarthritis cases. It provides effective pain management in patients with multiple joint conditions. This trend diversifies treatment applications and broadens patient reach. Viscosupplementation Market strengthens its role as a versatile therapy across orthopedic care. It enhances value for patients seeking alternatives to surgery for different joints.
For instance, a retrospective study of patients treated with HyalOne for symptomatic hip osteoarthritis found that at 24 months, 159 out of 176 patients (90%) did not require a total hip replacement (THR). Another retrospective pilot study of 224 hip OA patients treated with hylan G-F 20 found that 170 patients (75.9%) had a 24-month survival rate and avoided THR. In ankle OA, a study suggested efficacy for 3 HA injections in patients 3 weeks after arthroscopic treatment for osteochondral lesions of the talus.
Advances in Hyaluronic Acid Technology
Innovation in hyaluronic acid formulations improves durability and therapeutic outcomes. Cross-linking technologies create longer-lasting viscosupplements with better viscoelastic properties. It reduces the need for repeated injections and improves quality of life for patients. Companies are developing high-molecular-weight formulations that mimic natural synovial fluid more closely. The Viscosupplementation Market benefits from these advancements by addressing unmet needs in pain management. Continuous R&D investment ensures that newer formulations set higher standards for safety and efficacy.
Market Challenges Analysis
High Treatment Costs and Limited Reimbursement
The relatively high cost of viscosupplementation treatments remains a major barrier for widespread adoption. In many regions, reimbursement policies for these procedures are limited or inconsistent, restricting patient access. Viscosupplementation Market faces challenges in cost-sensitive healthcare systems where alternatives like corticosteroid injections are preferred due to affordability. It places financial strain on patients seeking long-term relief, especially for multi-injection regimens. Lack of standardized reimbursement frameworks discourages adoption in public healthcare programs. These financial hurdles limit growth despite clinical benefits.
Variable Clinical Outcomes and Regulatory Barriers
Clinical studies on viscosupplementation report mixed results regarding effectiveness, creating uncertainty among physicians and patients. Some trials show significant improvement, while others demonstrate only marginal benefits compared to placebo. Viscosupplementation Market must address these inconsistencies to strengthen physician confidence and adoption rates. It also faces strict regulatory scrutiny, with approval processes varying across regions. Stringent guidelines increase development costs and delay product launches, limiting market expansion. These clinical and regulatory challenges hinder broader acceptance of viscosupplementation as a standard therapy.
Market Opportunities
Rising Demand in Emerging Economies
Expanding healthcare infrastructure in emerging markets creates significant opportunities for viscosupplementation. Growing awareness of osteoarthritis treatments, combined with rising disposable incomes, increases patient willingness to adopt advanced therapies. Viscosupplementation Market benefits from the rising prevalence of joint disorders in aging populations across Asia-Pacific and Latin America. It provides non-surgical alternatives that reduce the burden on healthcare systems with limited surgical capacity. Favorable government initiatives supporting access to orthopedic treatments further enhance adoption. The opportunity to penetrate underserved regions strengthens long-term growth potential.
Advancements in Regenerative and Personalized Therapies
The integration of viscosupplementation with regenerative medicine approaches creates promising opportunities. Combining hyaluronic acid injections with platelet-rich plasma or stem cell therapies shows improved outcomes in cartilage preservation and pain relief. Viscosupplementation Market expands through these innovations, positioning itself as a key component in next-generation osteoarthritis management. It supports personalized medicine approaches by tailoring treatments to patient-specific needs. Advances in biomaterials and delivery systems enable longer-lasting results with fewer injections. These opportunities reinforce the role of viscosupplementation as an evolving therapy in modern orthopedic care.
Market Segmentation Analysis:
By Product
Viscosupplementation products are segmented into single-injection, three-injection, and five-injection regimens. Single-injection formulations are gaining strong traction due to convenience, reduced treatment time, and improved patient compliance. Three-injection regimens remain widely used because of their established efficacy and acceptance among physicians. Five-injection treatments are gradually declining as healthcare providers prefer shorter cycles to enhance patient satisfaction. Viscosupplementation Market expands across all product categories, with single-injection options driving innovation and multi-injection regimens maintaining relevance in traditional practice. It ensures patients have access to flexible treatment approaches tailored to disease severity and clinical preference.
For instance, Anika Therapeutics’ single-injection product, Monovisc, was shown in a clinical study to provide pain relief for up to 6 months after a single administration.
By Source of Origin
Viscosupplementation treatments are derived from both avian-based and non-animal-based sources. Avian-derived hyaluronic acid products have been in use for many years and remain significant in clinical practice. However, non-animal-based formulations are gaining momentum due to lower risk of allergic reactions and wider patient acceptance. These products also comply better with stringent safety regulations and align with the rising demand for sustainable and ethical sourcing. Viscosupplementation Market benefits from advancements in biotechnological production methods that improve purity and performance. It allows manufacturers to offer safer and more accessible treatment options across diverse patient groups.
For instance, LG Chem’s non-animal-based, single-dose viscosupplement Synovian (marketed as Hyruan ONE in some regions) was launched in China in July 2024, representing a significant new product in the bacterial fermentation category.
By End Use
End-use segmentation highlights adoption across hospitals, orthopedic clinics, and ambulatory surgical centers. Hospitals lead usage, supported by access to advanced treatment infrastructure and large patient volumes. Orthopedic clinics represent a rapidly growing segment, as they specialize in joint care and offer targeted therapies to osteoarthritis patients. Ambulatory surgical centers provide cost-effective and convenient treatment settings, expanding accessibility for patients outside major hospital networks. Viscosupplementation Market grows across these end-use segments by meeting the needs of both specialized and general healthcare providers. It ensures broader availability of viscosupplementation therapies in line with rising global demand for non-surgical joint pain solutions.
Segments:
Based on Product
Single injection
3 injections
5 injections
Based on Source of Origin
Avian origin
Non-avian origin
Based on End Use
Hospitals
Orthopedic clinics
Ambulatory surgical centers (ASCs)
Other end users
Based on the Geography:
North America
U.S.
Canada
Mexico
Europe
UK
France
Germany
Italy
Spain
Russia
Belgium
Netherlands
Austria
Sweden
Poland
Denmark
Switzerland
Rest of Europe
Asia Pacific
China
Japan
South Korea
India
Australia
Thailand
Indonesia
Vietnam
Malaysia
Philippines
Taiwan
Rest of Asia Pacific
Latin America
Brazil
Argentina
Peru
Chile
Colombia
Rest of Latin America
Middle East
UAE
KSA
Israel
Turkey
Iran
Rest of Middle East
Africa
Egypt
Nigeria
Algeria
Morocco
Rest of Africa
Regional Analysis
North America
North America holds a 38% share of the Viscosupplementation Market in 2024, driven by a high prevalence of osteoarthritis and an aging population. The United States leads adoption with advanced healthcare infrastructure, strong reimbursement frameworks, and rising awareness of non-surgical treatment alternatives. It also benefits from the presence of key market players introducing innovative single-injection therapies that reduce patient burden. Canada contributes with steady demand supported by government-funded healthcare programs that expand access to advanced therapies. Increasing incidence of obesity-related joint disorders further accelerates adoption in the region. Research collaborations between universities and pharmaceutical companies continue to advance new viscosupplementation formulations. Strong clinical acceptance and regulatory support keep North America as the global leader.
Europe
Europe accounts for a 29% share of the Viscosupplementation Market, supported by strong demand across Germany, France, Italy, and the U.K. The region benefits from rising osteoarthritis cases among elderly populations and high participation in sports activities that contribute to joint injuries. European Union healthcare policies encourage adoption of minimally invasive therapies, promoting viscosupplementation as an alternative to surgery. It also gains momentum through increasing preference for non-animal-based hyaluronic acid products that align with regional safety standards. Germany leads adoption due to its advanced orthopedic facilities, while France and Italy show rising demand supported by strong insurance coverage. Investments in clinical research continue to strengthen evidence supporting viscosupplementation use in multiple joints. Europe remains a strong growth hub due to its structured healthcare systems and patient awareness.
Asia-Pacific
Asia-Pacific commands a 24% share of the Viscosupplementation Market, making it the fastest-growing region. Large populations in China and India, combined with rapid urbanization, drive rising osteoarthritis prevalence. Japan and South Korea lead in technological advancements, offering innovative hyaluronic acid products with longer-lasting efficacy. It benefits from increasing healthcare investments and government initiatives that improve access to advanced orthopedic care. Growing adoption of single-injection regimens enhances convenience for patients in urban centers. Rising disposable incomes and expanding private healthcare infrastructure fuel stronger adoption across emerging economies. Asia-Pacific is positioned as a key growth engine with strong opportunities in both urban and rural healthcare systems.
Latin America
Latin America holds a 6% share of the Viscosupplementation Market, with Brazil and Mexico leading adoption. Rising cases of osteoarthritis due to aging populations and lifestyle changes drive demand for non-surgical therapies. The region benefits from expanding private healthcare services that introduce advanced treatment options. It also faces challenges with inconsistent reimbursement policies, limiting widespread adoption in public healthcare settings. Increasing participation in sports and higher obesity rates contribute to a growing patient pool requiring joint pain solutions. Brazil’s robust healthcare market supports wider use, while Mexico records steady demand through private clinics. Latin America demonstrates growth potential despite cost barriers.
Middle East & Africa
Middle East & Africa capture a 3% share of the Viscosupplementation Market, supported by expanding healthcare investments in Gulf countries and South Africa. Rising prevalence of osteoarthritis among aging populations creates strong demand for joint pain treatments. Countries such as the UAE and Saudi Arabia invest heavily in advanced orthopedic care, driving adoption of minimally invasive therapies. It also benefits from increasing awareness among patients seeking alternatives to joint replacement surgery. Limited reimbursement structures and reliance on imported products pose challenges to faster expansion. South Africa shows steady progress through private healthcare facilities offering viscosupplementation to a broader patient base. Growing infrastructure investments and partnerships with global healthcare providers strengthen long-term opportunities in the region.
Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!
Competitive landscape of the Viscosupplementation Market features leading players such as Anika Therapeutics, Bioventus, Fidia Pharma, Seikagaku Corporation, Avanos, Sanofi, Ferring Pharmaceuticals, APTISSEN, Premier Surgical, and Biotech Healthcare. These companies drive growth by focusing on advanced hyaluronic acid formulations, expansion into new joint applications, and improving patient compliance with single-injection regimens. Innovation remains central, with several firms investing in cross-linked and high-molecular-weight products that extend treatment effectiveness and reduce injection frequency. Strategic partnerships and acquisitions strengthen their distribution networks and global reach, ensuring accessibility across both developed and emerging healthcare systems. Companies emphasize clinical validation and regulatory approvals to differentiate their products in a competitive market where safety and efficacy are critical. Rising demand for minimally invasive osteoarthritis therapies fuels competition, pushing players to align offerings with reimbursement frameworks and patient affordability. With expanding applications in hip, shoulder, and ankle osteoarthritis, these firms position viscosupplementation as an essential non-surgical solution, reinforcing their leadership in orthopedic care.
Recent Developments
In July 2025, Anika Therapeutics reported a 41 percent increase in Regenerative Solutions revenue, driven by strong performance of the Integrity Implant System and continued growth of Hyalofast®.
In May 2025, Anika confirmed that Integrity Implant System launched in 2024 has shown over 40 percent sequential growth, and is projected to more than double its revenue in 2025.
In May 2025, Anika Therapeutics noted that the final PMA module for Hyalofast® is on track for filing in the second half of the year, enabling a planned U.S. launch in 2026.
In March 2025, Anika Therapeutics closed the sale of Parcus Medical to Medacta Group, enabling the company to concentrate resources on hyaluronic acid-based pain solutions.
Report Coverage
The research report offers an in-depth analysis based on Product,Source of Origin,End Use and Geography. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.
Future Outlook
Demand for single-injection therapies will increase due to improved compliance and convenience.
Advances in cross-linked hyaluronic acid will extend treatment duration and effectiveness.
Integration with platelet-rich plasma and stem cell therapies will expand clinical applications.
Expansion into hip, shoulder, and ankle osteoarthritis will diversify product use.
Aging populations worldwide will continue to drive adoption of non-surgical joint care.
Growth in sports medicine will strengthen demand among younger and active patients.
Emerging markets in Asia-Pacific and Latin America will provide strong growth opportunities.
Digital health tools will support monitoring of patient outcomes after injections.
Regulatory approvals for next-generation formulations will accelerate global product launches.
Strategic partnerships and acquisitions will enhance distribution networks and market penetration.
Introduction
1.1. Report Description
1.2. Purpose of the Report
1.3. USP & Key Offerings
1.4. Key Benefits for Stakeholders
1.5. Target Audience
1.6. Report Scope
1.7. Regional Scope
Scope and Methodology
2.1. Objectives of the Study
2.2. Stakeholders
2.3. Data Sources
2.3.1. Primary Sources
2.3.2. Secondary Sources
2.4. Market Estimation
2.4.1. Bottom-Up Approach
2.4.2. Top-Down Approach
2.5. Forecasting Methodology
Executive Summary
Introduction
4.1. Overview
4.2. Key Industry Trends
Global Viscosupplementation Market
5.1. Market Overview
5.2. Market Performance
5.3. Impact of COVID-19
5.4. Market Forecast
Market Breakup by Product
6.1. Single Injection
6.1.1. Market Trends
6.1.2. Market Forecast
6.1.3. Revenue Share
6.1.4. Revenue Growth Opportunity
6.2. 3 Injections
6.2.1. Market Trends
6.2.2. Market Forecast
6.2.3. Revenue Share
6.2.4. Revenue Growth Opportunity
6.3. 5 Injections
6.3.1. Market Trends
6.3.2. Market Forecast
6.3.3. Revenue Share
6.3.4. Revenue Growth Opportunity
Market Breakup by Source of Origin
7.1. Avian Origin
7.1.1. Market Trends
7.1.2. Market Forecast
7.1.3. Revenue Share
7.1.4. Revenue Growth Opportunity
7.2. Non-Avian Origin
7.2.1. Market Trends
7.2.2. Market Forecast
7.2.3. Revenue Share
7.2.4. Revenue Growth Opportunity
Market Breakup by End Use
8.1. Hospitals
8.1.1. Market Trends
8.1.2. Market Forecast
8.1.3. Revenue Share
8.1.4. Revenue Growth Opportunity
8.2. Orthopedic Clinics
8.2.1. Market Trends
8.2.2. Market Forecast
8.2.3. Revenue Share
8.2.4. Revenue Growth Opportunity
8.3. Ambulatory Surgical Centers (ASCs)
8.3.1. Market Trends
8.3.2. Market Forecast
8.3.3. Revenue Share
8.3.4. Revenue Growth Opportunity
8.4. Other End Users
8.4.1. Market Trends
8.4.2. Market Forecast
8.4.3. Revenue Share
8.4.4. Revenue Growth Opportunity
Market Breakup by Region
9.1. North America
9.1.1. United States
9.1.1.1. Market Trends
9.1.1.2. Market Forecast
9.1.2. Canada
9.1.2.1. Market Trends
9.1.2.2. Market Forecast
9.2. Asia-Pacific
9.2.1. China
9.2.2. Japan
9.2.3. India
9.2.4. South Korea
9.2.5. Australia
9.2.6. Indonesia
9.2.7. Others
9.3. Europe
9.3.1. Germany
9.3.2. France
9.3.3. United Kingdom
9.3.4. Italy
9.3.5. Spain
9.3.6. Russia
9.3.7. Others
9.4. Latin America
9.4.1. Brazil
9.4.2. Mexico
9.4.3. Others
9.5. Middle East and Africa
9.5.1. Market Trends
9.5.2. Market Breakup by Country
9.5.3. Market Forecast
SWOT Analysis
10.1. Overview
10.2. Strengths
10.3. Weaknesses
10.4. Opportunities
10.5. Threats
Value Chain Analysis
Porter’s Five Forces Analysis
12.1. Overview
12.2. Bargaining Power of Buyers
12.3. Bargaining Power of Suppliers
12.4. Degree of Competition
12.5. Threat of New Entrants
12.6. Threat of Substitutes
Price Analysis
Competitive Landscape
14.1. Market Structure
14.2. Key Players
14.3. Profiles of Key Players
14.3.1. Bioventus
14.3.1.1. Company Overview
14.3.1.2. Product Portfolio
14.3.1.3. Financials
14.3.1.4. SWOT Analysis
14.3.2. Premier Surgical
14.3.3. Sanofi
14.3.4. Ferring Pharmaceuticals
14.3.5. Seikagaku Corporation
14.3.6. APTISSEN
14.3.7. Anika Therapeutics
14.3.8. Fidia Pharma
14.3.9. Avanos
14.3.10. Biotech Healthcare
Research Methodology
Request A Free Sample
We prioritize the confidentiality and security of your data. Our promise: your information remains private.
Ready to Transform Data into Decisions?
Request Your Sample Report and Start Your Journey of Informed Choices
Providing the strategic compass for industry titans.
Frequently Asked Questions:
What is the current market size for Viscosupplementation, and what is its projected size in 2032?
The Viscosupplementation Market was valued at USD 5.29 billion in 2024 and is projected to reach USD 8.37 billion by 2032.
At what Compound Annual Growth Rate is the Viscosupplementation market projected to grow between 2025 and 2032?
The Viscosupplementation Market is projected to grow at a CAGR of 5.91% between 2025 and 2032.
Which Viscosupplementation market segment held the largest share in 2024?
The single-injection segment held the largest share of the Viscosupplementation Market in 2024.
What are the primary factors fueling the growth of the Viscosupplementation market?
The Viscosupplementation Market grows through rising osteoarthritis prevalence, an aging population, and increasing demand for non-surgical therapies.
Who are the leading companies in the Viscosupplementation market?
Key companies in the Viscosupplementation Market include Anika Therapeutics, Bioventus, Fidia Pharma, and Seikagaku Corporation.
Which region commanded the largest share of the Viscosupplementation market in 2024?
North America commanded the largest share of the Viscosupplementation Market in 2024.
About Author
Shweta Bisht
Healthcare & Biotech Analyst
Shweta is a healthcare and biotech researcher with strong analytical skills in chemical and agri domains.
Medium Voltage Wire and Cable Market size was valued at USD 64.69 billion in 2024 and is anticipated to reach USD 111.15 billion by 2032, at a CAGR of 7% during the forecast period.
The Fire Tube Industrial Boiler Market size was valued at USD 5.8 billion in 2024 and is expected to reach USD 8.4 billion by 2032, growing at a CAGR of 4.8% during the forecast period.
First Mile Delivery Market size was valued at USD 4.8 billion in 2024 and is anticipated to reach USD 9.4 billion by 2032, at a CAGR of 8.8% during the forecast period.
Fire Suppression Market size was valued at USD 6.5 billion in 2024 and is anticipated to reach USD 9.4 billion by 2032, at a CAGR of 4.8% during the forecast period.
Fire Sprinkler Systems Market size was valued at USD 11.2 billion in 2024 and is anticipated to reach USD 15.3 billion by 2032, at a CAGR of 4% during the forecast period.
Fire Resistant Cable Market size was valued at USD 8.3 billion in 2024 and is anticipated to reach USD 12 billion by 2032, at a CAGR of 4.7% during the forecast period.
Extrusion Coatings Market size was valued at USD 4.7 billion in 2024 and is anticipated to reach USD 7 billion by 2032, at a CAGR of 5.1% during the forecast period.
Exercise and Weight Loss Apps Market size was valued at USD 4.1 billion in 2024 and is anticipated to reach USD 11.8 billion by 2032, at a CAGR of 14.2% during the forecast period.
EV Traction Inverter Market size was valued at USD 5.6 billion in 2024 and is anticipated to reach USD 15.2 billion by 2032, at a CAGR of 13.3% during the forecast period.
Licence Option
The report comes as a view-only PDF document, optimized for individual clients. This version is recommended for personal digital use and does not allow printing. Use restricted to one purchaser only.
$4999
To meet the needs of modern corporate teams, our report comes in two formats: a printable PDF and a data-rich Excel sheet. This package is optimized for internal analysis. Unlimited users allowed within one corporate location (e.g., regional office).
$6999
The report will be delivered in printable PDF format along with the report’s data Excel sheet. This license offers 100 Free Analyst hours where the client can utilize Credence Research Inc. research team. Permitted for unlimited global use by all users within the purchasing corporation, such as all employees of a single company.
Thank you for the data! The numbers are exactly what we asked for and what we need to build our business case.
Materials Scientist (privacy requested)
The report was an excellent overview of the Industrial Burners market. This report does a great job of breaking everything down into manageable chunks.
